Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Pursuing PARP Beyond HRD+ Ovarian Cancer

April 9th 2021

Hye Sook Chon, MD, teases out some of the differences between the data with PARP inhibitors in the frontline maintenance setting and shed light on ongoing research with combinations that could broaden their utility in patients with advanced ovarian cancer.

Utility of HRD Testing in Ovarian Cancer Expands, but Standardization Remains Elusive

April 6th 2021

Thomas C. Krivak, MD, discusses the significance of HRD in ovarian cancer, approved and prospective HRD tests, and considerations for genomic testing in this population.

Study Examines Cost-Sharing Trends in PARP Inhibitors for Ovarian Cancer

April 2nd 2021

Out-of-pocket costs for patients with ovarian cancer who have been treated with PARP inhibitors are generally low, according to recent study results from a single institution.

Dr. Wenham on Future Directions with Antibody-Drug Conjugates in Ovarian Cancer

March 30th 2021

Robert Wenham, MD, MS, FACOG, FACS, discusses future directions with antibody-drug conjugates in the treatment of patients with ovarian cancer.

Mirvetuximab Soravtansine/Rucaparib Shows Early Tolerability, Activity in Ovarian and Endometrial Cancers

March 29th 2021

The combination of mirvetuximab soravtansine and rucaparib was found to be well tolerated, with encouraging activity reported in heavily pretreated patients with endometrial, ovarian, fallopian tube, or primary peritoneal cancer.

Coleman and Brown Review Advancing Applications for PARP Inhibition in Ovarian Cancer

March 25th 2021

Dr. Coleman and Dr. Brown discuss how understandings of BRCA and patient eligibility for PARP inhibitors have evolved in ovarian cancer, the effects of frontline maintenance trials on treatment recommendations, the clinical significance of the findings from the ARIEL4 trial, and where PARP inhibition is headed in the field.

Farletuzumab/Chemo Fails to Improve PFS in Platinum-Sensitive, Recurrent Ovarian Cancer With Low CA-125

March 25th 2021

The addition of farletuzumab to carboplatin plus paclitaxel or carboplatin plus pegylated liposomal doxorubicin did not demonstrate superiority over placebo plus chemotherapy in patients with platinum-sensitive recurrent ovarian cancer who are in their first relapse and have low cancer antigen-125 levels.

Mirvetuximab Soravtansine Monotherapy Under Exploration in Platinum-Resistant FRα+ Ovarian Cancer

March 25th 2021

The exploration of mirvetuximab soravtansine as a potentially efficacious treatment in patients with advanced, high-grade, platinum-resistant epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor–alpha expression continues with the ongoing, single-arm, phase 3 SORAYA trial.

Dostarlimab Delivers Durable Responses in dMMR/MMRp Endometrial Cancer

March 24th 2021

Dostarlimab demonstrated durable antitumor activity in patients with mismatch repair deficient and MMR proficient endometrial cancer, regardless of investigator assessment or blinded independent central review and immune-related RECIST or RECIST v1.1 criteria.

AVB-500/Paclitaxel Demonstrates Clinical Benefit in Platinum-Resistant Ovarian Cancer

March 23rd 2021

The GAS6/AXL inhibitor AVB-500, when combined with paclitaxel, elicited clinical benefit with favorable tolerability in patients with platinum-resistant ovarian cancer, according to data from a phase 1b study.

PARP Inhibition Presses Forward With the Possibility of Retreatment and Combo Approaches in Ovarian Cancer

March 23rd 2021

Jing-Yi Chern, MD, ScM, discusses the role of maintenance PARP inhibition in patients with recurrent platinum-sensitive ovarian cancer, as well as remaining questions regarding the utility of PARP inhibitors in this setting.

Dr. Hamilton on the Evaluation of Lucitanib/Nivolumab in Gynecologic Cancers

March 22nd 2021

Erika P. Hamilton, MD, discusses the phase 2 LIO-1 trial evaluation of lucitanib and nivolumab across different gynecologic cancer subtypes.

Olaparib Maintains Acceptable Safety Profile in Platinum-Sensitive, Relapsed Ovarian Cancer

March 22nd 2021

Olaparib, when used in patients with platinum-sensitive relapsed ovarian cancer who had a known BRCA mutation and homologous recombination deficiency status, demonstrated adverse effects that proved to be consistent with the established safety profile of the PARP inhibitor.

Maintenance Niraparib Maintains PFS Improvement in gBRCA+/- Ovarian Cancer

March 22nd 2021

Maintenance niraparib demonstrated clinical benefit that persisted beyond first progression in patients with platinum-sensitive recurrent ovarian cancer with or without germline BRCA mutations.  

Olaparib/Cediranib Fails to Significantly Improve PFS Over Cediranib Alone in Advanced Endometrial Cancer

March 22nd 2021

Although the combination of olaparib and cediranib showcased modest efficacy over cediranib alone in patients with recurrent, metastatic or persistent endometrial cancer, the difference was not statistically significant.

Maintenance Olaparib Maintains PFS Benefit at 5 Years in Ovarian Cancer

March 21st 2021

Maintenance olaparib showcased progression-free survival benefit in almost half of the patients with ovarian cancer vs 21% of those who received placebo, including consistent benefit in high- and low-risk patients.

Niraparib/Bevacizumab Continues to Showcase PFS Benefit in Advanced Ovarian Cancer

March 21st 2021

Niraparib in combination with bevacizumab continued to showcase a progression-free survival benefit in patients with advanced ovarian cancer who previously received frontline platinum-based chemotherapy and bevacizumab.

Eribulin Demonstrates Limited Activity in Advanced or Recurrent Cervical Cancer

March 20th 2021

Eribulin induced limited activity with a favorable toxicity profile in patients with recurrent or advanced cervical cancer, and prior exposure to paclitaxel was associated with decreased response to the agent.

Dostarlimab Triplet Shows Antitumor Activity, Tolerability in Ovarian Cancer

March 20th 2021

Dostarlimab plus niraparib and bevacizumab showcased favorable antitumor activity and tolerability in patients with platinum-resistant ovarian cancer.

Pembrolizumab/Lenvatinib Improves Survival, ORR in Advanced Endometrial Cancer, Regardless of MMR Status

March 20th 2021

The combination of pembrolizumab and lenvatinib improved progression-free and overall survival, as well as response rates, compared with chemotherapy in patients with advanced endometrial cancer who received prior platinum-based chemotherapy, irrespective of mismatch repair status, according to phase 3 findings of the Study-309/KEYNOTE-775 trial.